



## **Shilpa Medicare Limited**

### **Corporate & Admin Office:**

“Shilpa House”, # 12-6-214/A-1, Hyderabad Road,  
Raichur – 584 135, Karnataka, India

Tel: +91-8532-238704, Fax: +91-8532-238876

Email: info@vbshilpa.com, Web: www.vbshilpa.com

CIN: L85110KA1987PLC008739

Dated: January 19,2024

Corporate Relationship Department,  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
MUMBAI-400 001

National Stock Exchange of India Ltd.  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No.C/1, G Block  
Bandra Kurla Complex, Bandra (E)  
MUMBAI-400 051

Dear Sir/Madam,

**Sub: Intimation U/R 30 of the SEBI(LODR) Regulations- Reg.**

**Ref: Stock Code: NSE: SHILPAMED/BSE-530549**

.....

### **Europe Approval for Amifampridine Tablets, 10 mg**

This is to inform you that Shilpa Medicare Limited, headquartered at Raichur, Karnataka, India, has received Marketing Authorization from Germany, EU for Amifampridine Tablets, 10 mg under the National Procedure.

Amifampridine is used as a drug, predominantly in the treatment of a number of rare muscle diseases. Specifically, Amifampridine is used to treat Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disease.

This product has sales of about 20 M USD in Europe. As on date, there is one other approved generic in the market.

With Regards,

For and on behalf of  
**SHILPA MEDICARE LIMITED**

Ritu Tiwary  
Company Secretary & Compliance Officer